» Articles » PMID: 36658148

Structural Basis for a Conserved Neutralization Epitope on the Receptor-binding Domain of SARS-CoV-2

Abstract

Antibody-mediated immunity plays a crucial role in protection against SARS-CoV-2 infection. We isolated a panel of neutralizing anti-receptor-binding domain (RBD) antibodies elicited upon natural infection and vaccination and showed that they recognize an immunogenic patch on the internal surface of the core RBD, which faces inwards and is hidden in the "down" state. These antibodies broadly neutralize wild type (Wuhan-Hu-1) SARS-CoV-2, Beta and Delta variants and some are effective against other sarbecoviruses. We observed a continuum of partially overlapping antibody epitopes from lower to upper part of the inner face of the RBD and some antibodies extend towards the receptor-binding motif. The majority of antibodies are substantially compromised by three mutational hotspots (S371L/F, S373P and S375F) in the lower part of the Omicron BA.1, BA.2 and BA.4/5 RBD. By contrast, antibody IY-2A induces a partial unfolding of this variable region and interacts with a conserved conformational epitope to tolerate all antigenic variations and neutralize diverse sarbecoviruses as well. This finding establishes that antibody recognition is not limited to the normal surface structures on the RBD. In conclusion, the delineation of functionally and structurally conserved RBD epitopes highlights potential vaccine and therapeutic candidates for COVID-19.

Citing Articles

The Compensatory Effect of S375F on S371F Is Vital for Maintaining the Infectivity of SARS-CoV-2 Omicron Variants.

Liu S, Liu P, Lu Q, Shen Y, Zhang L, Liang Z J Med Virol. 2025; 97(3):e70242.

PMID: 40062404 PMC: 11891949. DOI: 10.1002/jmv.70242.


Epitope-focused vaccine immunogens design using tailored horseshoe-shaped scaffold.

Zhao F, Zhang Y, Zhang Z, Chen Z, Wang X, Wang S J Nanobiotechnology. 2025; 23(1):119.

PMID: 39966941 PMC: 11834273. DOI: 10.1186/s12951-025-03200-9.


Visual and High-Efficiency Secretion of SARS-CoV-2 Nanobodies with .

Zhao S, Zeng W, Yu F, Xu P, Chen C, Chen W Biomolecules. 2025; 15(1).

PMID: 39858505 PMC: 11762740. DOI: 10.3390/biom15010111.


The molecular reach of antibodies crucially underpins their viral neutralisation capacity.

Huhn A, Nissley D, Wilson D, Kutuzov M, Donat R, Tan T Nat Commun. 2025; 16(1):338.

PMID: 39746910 PMC: 11695720. DOI: 10.1038/s41467-024-54916-5.


Structural Immunology of SARS-CoV-2.

Yuan M, Wilson I Immunol Rev. 2024; 329(1):e13431.

PMID: 39731211 PMC: 11727448. DOI: 10.1111/imr.13431.


References
1.
Cohen A, van Doremalen N, Greaney A, Andersen H, Sharma A, Starr T . Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science. 2022; 377(6606):eabq0839. PMC: 9273039. DOI: 10.1126/science.abq0839. View

2.
Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

3.
Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L . BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022; 608(7923):593-602. PMC: 9385493. DOI: 10.1038/s41586-022-04980-y. View

4.
Huo J, Zhao Y, Ren J, Zhou D, Duyvesteyn H, Ginn H . Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. Cell Host Microbe. 2020; 28(3):445-454.e6. PMC: 7303615. DOI: 10.1016/j.chom.2020.06.010. View

5.
West Jr A, Scharf L, Horwitz J, Klein F, Nussenzweig M, Bjorkman P . Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proc Natl Acad Sci U S A. 2013; 110(26):10598-603. PMC: 3696754. DOI: 10.1073/pnas.1309215110. View